TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34051389
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of HPV vaccine
Study: 34051389
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HPV vaccine
Study: 34159751
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of amlodipine 5 mg, losartan 100 mg, and chlorthalidone 25 mg
Study: 34159751
Drug: Separate components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate components (loose combination) of amlodipine/losartan 5/100 mg and chlorthalidone 25 mg
Study: 38844004
Drug: Fluticasone furoate/umeclidinium/vilanterol
Normalized name: Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy
Study: 33910578
Drug: Fibrinogen levels
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen levels ≥ 3.5 g/L
Study: 35296402
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment (Alirocumab vs Placebo)
Study: 36480510
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (20 minutes at 2 mA) for 10 daily sessions plus 5 follow up sessions
Study: 36480510
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS (30 seconds at 2 mA, 19 minutes at 0 mA) for 10 daily sessions plus 5 follow up sessions
Study: 35149568
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving treatment as usual, no CIH counselling
Study: 34034627
Drug: Random forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random forest algorithm for predicting problem coping experiences (PCE) effects in cognitive-behavioral therapy
Study: 34321058
Drug: Immediate tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate tapering of opioids
Study: 32440730
Drug: Inulin-type fructans
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin-type fructans (16 g)
Study: 32440730
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 16 g)
Study: 34344029
Drug: Givosiran (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givosiran (monthly subcutaneous injection)
Study: 32711554
Drug: High-dose platinum-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose platinum-based chemotherapy
Study: 35089960
Drug: Metformin (2g/day)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (2g/day)
Study: 35089960
Drug: Metformin and
Normalized name: metformin and acarbose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin and Placebo (PCOS mothers)
Study: 33650197
Drug: Losartan, 25
Normalized name: Hydrochlorothiazide-Losartan, 25 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 25 mg, twice a day
Study: 33650197
Drug: Amlodipine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, 5 mg per day
Study: 32975161
Drug: Ureteral catheter
Normalized name: Bos taurus ureter preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureteral catheter treatment
Study: 35988167
Drug: CNP‐EPI (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNP‐EPI (1 mL subcutaneously injected 1 day before surgery)
Study: 34252267
Drug: Horyzons online
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Horyzons online therapy
Study: 32468765
Drug: Prophylactic pre-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic pre-operative antibiotics
Study: 35939865
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lacticaseibacillus paracasei SD1, L. rhamnosus SD4, L. rhamnosus SD11, Limosilactobacillus fermentum SD7)
Study: 34276009
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (canagliflozin 100 mg/day or dapagliflozin 5 mg/day or empagliflozin 10 mg/day)
Study: 32621449
Drug: Razi vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Razi vaccine
Study: 32621449
Drug: Dn vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dn vaccine
Study: 32621449
Drug: Vc vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vc vaccine
Study: 32621449
Drug: Ch vaccine
Normalized name: typhoid VI polysacch vaccine 25 mcg/0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ch vaccine
Study: 35652323
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (LI) involving cognitive behavioral therapy (CBT)
Study: 35218191
Drug: l-methionine (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-methionine (reference diet) at 0.5, 1, 2, and 3 mg.kg-1.d-1
Study: 33397427
Drug: High-dose heparinization
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose heparinization aiming for an activated clotting time (ACT) of 140–180 s
Study: 33397427
Drug: Low-dose heparinization
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparinization aiming for a partial thromboplastin time (PTT) of 35–40 s
Study: 33548518
Drug: Tree SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tree SLIT-tablet (12 SQ-Bet)
Study: 36064525
Drug: Genetically-proxied beta-blocker
Normalized name: Agalsidase beta (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically-proxied beta-blocker (BB)
Study: 36064525
Drug: Genetically-proxied calcium
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically-proxied calcium channel blocker (CCB)
Study: 33370444
Drug: Embedded athletic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embedded athletic training musculoskeletal care model (2 certified athletic trainers and a sports medicine fellowship‐trained physician)
Study: 36404525
Drug: Futibatinib 20
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futibatinib 20 mg
Study: 36404525
Drug: Futibatinib 80
Normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futibatinib 80 mg
Study: 33565691
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg once-daily)
Study: 33565691
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg once-daily)
Study: 35583344
Drug: Rifampicin (RIF)
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (RIF) added to DRV/r 800/100 mg once daily (QD) and then DRV/r 800/100 twice daily (BD) and 1,600/200 QD
Study: 35583344
Drug: DRV/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 800/100 mg once daily (QD)
Study: 33191251
Drug: Permissive hypotension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive hypotension (vasopressor titration to achieve MAP 60-65 mm Hg)
Study: 33689654
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment videogame
Study: 32996027
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS with self-care guidelines for managing side effects
Study: 34562610
Drug: Nivolumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (1 mg/kg, Q3W) plus ipilimumab (3 mg/kg, Q3W) followed by nivolumab monotherapy (240 mg, Q2W) for up to 12 months
Study: 34453234
Drug: Favipiravir (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (1800 mg twice a day on Day 1, followed by 800 mg twice a day for up to 13 days)
Study: 36374742
Drug: drug-laser-photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug-laser-photon therapy
Study: 36254422
Drug: Dexmedetomidine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 25 mcg
Study: 36254422
Drug: Dexmedetomidine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 50 mcg
Study: 36254422
Drug: Dexmedetomidine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 75 mcg
Study: 36254422
Drug: Dexmedetomidine 100
Normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 100 mcg
Study: 33883768
Drug: Dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg (2mls of 4mg/ml)
Study: 33021328
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered early, <3h post-injury
Study: 32635281
Drug: Aquatic Ai
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic Ai Chi therapy
Study: 32635281
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (alternating sessions of physiotherapy on dry land and aquatic Ai Chi therapy)
Study: 32635281
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment on dry land (control group)
Study: 34352829
Drug: 12‐mL paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐mL paracervical block
Study: 34352829
Drug: 20‐mL paracervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL paracervical block
Study: 32693214
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of stable dose of combination inhaled corticosteroid-long-acting beta-agonist
Study: 32693214
Drug: Step-down of
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down of inhaled corticosteroid
Study: 32693214
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of long-acting bronchodilator
Study: 32144908
Drug: Herbal cake-partitioned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal cake-partitioned moxibustion combined with Rhinocort spray (256 µg/d, once in the morning and evening, for 4 weeks)
Study: 32144908
Drug: Rhinocort spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinocort spray alone (256 µg/d, once in the morning and evening, for 4 weeks)
Study: 32593524
Drug: Ursolic acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursolic acid (UA) 400 mg/d
Study: 32593524
Drug: Placebo 400
Normalized name: placebo 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg/d
Study: 36089810
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg + Losartan 50 mg
Study: 33971067
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (major autohemotherapy) applied to 37 patients, consisting of seven sessions of intravenous ozone administration (100 mL, 30 μg/mL)
Study: 33971067
Drug: Conventional COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional COVID-19 treatment applied to 18 patients in the control group
Study: 35169095
Drug: Bevacizumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor.
Study: 33188747
Drug: Nitazoxanide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (1.0 g/day) for 14 days
Study: 33188747
Drug: Mesalazine (1.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (1.5-2 g/day) for 14 days
Study: 33188747
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitazoxanide (1.0 g/day) and mesalazine (≥1.5-2 g/day) for 14 days
Study: 33866933
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of 100 mg oral ferrous fumarate
Study: 33866933
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day intake of 100 mg oral ferrous fumarate
Study: 33006615
Drug: Cold Atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Atmospheric Plasma Therapy
Study: 33006615
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Therapy Placebo
Study: 35258042
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) twice per day for 7 days before surgery
Study: 33955943
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with intrascleral collagen implant (DSCI)
Study: 33955943
Drug: Deep sclerectomy
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep sclerectomy with suprachoroidal collagen implant (DSSCI)
Study: 34707516
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (including but not limited to antidepressant medication and/or psychotherapy)
Study: 33010094
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no homeopathic treatment)
Study: 35577034
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine (LDX) 10, 20, 30 mg pooled
Study: 33846555
Drug: Colostrum (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostrum (200 mg/L)
Study: 33846555
Drug: Transitional milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitional milk (171 mg/L)
Study: 33846555
Drug: Mature milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mature milk (126 mg/L)
Study: 33992249
Drug: Pilates training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates training (2 to 4 weekly sessions for 10 weeks)
Study: 32964939
Drug: Fresh embryo
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh embryo transfer with intensified luteal phase support (1500 IU hCG, oral estradiol 2 mg twice daily, micronized vaginal progesterone 200 mg three times daily)
Study: 34268513
Drug: Therapeutic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic heparin
Study: 35099997
Drug: Prophylactic-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic-dose heparin
Study: 39709402
Drug: L-PRF alone
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF alone
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 10 mg Zn/kg feed
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 20 mg Zn/kg feed
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 40 mg Zn/kg feed
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 80 mg Zn/kg feed
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet supplemented with 160 mg Zn/kg feed
Study: 32416830
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet (27.7 mg/kg Zn)
Study: 35848821
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 ml triamcinolone 40 mg/ml under ultrasound guidance)
Study: 33783516
Drug: Shortened duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened duration of adjuvant chemotherapy (3 to 5 months) with CAPOX (capecitabine plus oxaliplatin)
Study: 33783516
Drug: Shortened duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened duration of adjuvant chemotherapy (3 to 5 months) with FOLFOX (5-fluorouracil/leucovorin plus oxaliplatin)
Study: 33210651
Drug: Essential drugs
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential drugs prescribed
Study: 33210651
Drug: Medicines prescribed
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medicines prescribed in generic names
Study: 33210651
Drug: Adequate response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adequate response on medicine use
Study: 36226787
Drug: Patient-directed arm
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-directed arm (0-30 tablets of oxycodone 5 mg)
Study: 36226787
Drug: Standard arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm (30 tablets of oxycodone 5 mg)
Study: 35035944
Drug: SNF472 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNF472 (7 mg/kg intravenously) three times weekly for 12 weeks
Study: 35035944
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times weekly for 12 weeks
Study: 33595213
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone calls by a clinical dietitian for 3 months
Study: 33955190
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus intensity-modulated radiotherapy (IC+RT)
Study: 33955190
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy plus IMRT (CCRT)
Study: 32579549
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing 2.6g of amino acids and 250 mcg of chromium picolinate
Study: 34006256
Drug: Neural network
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neural network models using 12 sequential fever data for predicting RMPP-5
Study: 32873500
Drug: Sublingual buprenorphine–naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine–naloxone
Study: 33801665
Drug: Beetroot Juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot Juice (BJ) 140 mL (12.8 mmol NO3−)
Study: 32405071
Drug: Continued ACEI/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued ACEI/ARB treatment
Study: 32405071
Drug: Temporary discontinuation
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary discontinuation of ACEI/ARB treatment for 30 days
Study: 32955913
Drug: Triphala (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphala (2,000 mg daily for 4 weeks)
Study: 32955913
Drug: Manjistha (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manjistha (2,000 mg daily for 4 weeks)
Study: 32955913
Drug: Placebo (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2,000 mg daily for 4 weeks)
Study: 34610941
Drug: HABIT-ILE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HABIT-ILE therapy
Study: 34610941
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity conventional therapy
Study: 32459653
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders, feedback, and gain-framed nominal financial incentives (Arm 1)
Study: 32459653
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders and feedback only (Arm 2)
Study: 33111581
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran (30 g/day) plus navy bean (30 g/day)
Study: 33111581
Drug: Fibersol‐2® (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibersol‐2® (10 g/day)
Study: 36365080
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser-assisted delivery of methotrexate (AFL+MTX) therapy
Study: 36365080
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional laser (AFL) therapy
Study: 35613766
Drug: Statins alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors
Study: 33939245
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg of budesonide daily for 3 months
Study: 35513132
Drug: Photon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon therapy (XT)
Study: 33141635
Drug: Yellow passion
Normalized name: PASSION FLOWER
DrugBank: Passiflora incarnata flower (DB13974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow passion fruit albedo flour (FAMA) 500 mg capsules, three times a day
Study: 33141635
Drug: Long turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long turmeric capsules (CURPI) 500 mg merged with piperine (5 mg)
Study: 33141635
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of carboxymethyl cellulose (500 mg)
Study: 35617704
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus rhamnosus GG; L.GG)
Study: 33034421
Drug: Nuvaring® vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuvaring® vs Injection
Study: 33034421
Drug: Injection vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection vs Nuvaring®
Study: 33034421
Drug: Injection vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection vs COC
Study: 32485993
Drug: 430 mg
Normalized name: urea 430 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 430 mg green oat extract